Clinical benefit from immune checkpoint inhibition in advanced melanoma and NSCLC can be predicted by tyrosine kinase activity profiling

Blood-based biomarker test has the potential to decrease the number of both over- and undertreated patients improving overall response rate, reduce unnecessary side effects and help saving costs.

PamGene, a biotech and services company focused on the development and commercialization of multiple novel biomarker panels for patient stratification in immuno-oncology, presented positive interim-results of its current multi-cohort study at ESMO. The study’s objective is to validate the predictive value of PamGene’s diagnostic blood test, the IOpener™, intended for rapid prediction of the likelihood of a patient’s response to immune checkpoint inhibitors (ICI) therapy by tyrosine kinase activity profiling. Based on these very promising results validation studies in combination with existing biomarkers are currently taking place.

Read further